What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Viloxazine extended-release capsules administered orally once daily in the morning for 8 weeks. The starting dose is 100 mg once daily. The dose may be increased by 100 mg weekly during titration, up to 400 mg once daily, based on investigator assessment of tolerability and response. The maintenance dose will be 200 mg, 300 mg, or 400 mg once daily.”In the company’s words, NCT07678827 on ClinicalTrials.gov
- Tested for
- Attention Deficit Hyperactivity Disorder, Attention-Deficit / Hyperactivity Disorder, ADHD
- Main trialPhase 3
- “This is a Phase 3, randomized, double-blind, placebo-controlled, multicenter bridging clinical trial designed to evaluate the efficacy and safety of viloxazine extended-release capsules (AK-D101) compared with placebo in Korean children and adolescents aged 6 to 17 years with attention-deficit/hyperactivity disorder (ADHD). Eligible participants will be randomized in a 1:1 ratio to receive AK-D101 or placebo once daily for 8 weeks. Randomization will be stratified by study site and age group (children aged 6 to 11 years and adolescents aged 12 to 17 years). The primary efficacy endpoint is…”In the company’s words, NCT07678827 on ClinicalTrials.gov
Other drugs for Attention Deficit Hyperactivity Disorder
- CentanafadineOtsuka · Phase 3
- SolriamfetolAxsome Therapeutics, Inc. · Phase 3
- ALKS 7290Alkermes, Inc. · Phase 2
- SPN-812Supernus Pharmaceuticals, Inc. · Marketed (Phase 4 trial)
Coming up1
- Sep 2027Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Not yet recruiting | Sep 2027 | A Phase 3 Study of Viloxazine ER Capsules in Korean Children and Adolescents With ADHD |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026